DGAP-News: GBC AG / Key word(s): Conference/Miscellaneous
Dear Sir or Madam,
We hereby warmly invite you to the Digital Roadshow/Corporate Presentation of Cardiol Therapeutics Inc. (ISIN CA14161Y2006) on the latest developments. The presentation will take place on Nov. 24, 2021 at 3:00 pm.
With the completion of the Public Offering, the company will have raised more than $ 52.4 million in cash. Included is $ 2.4 million from the warrants' accelerated expiration date of June 4, 2020. On November 2nd, the company filed a preliminary prospectus, and on November 3rd, the company announced the pricing. Cardiol Therapeutics announced the closing of its $50 million public offering less than 24 hours later. This demonstrates the American markets' appetite for Cardiol Therapeutics and the significance of their NASDAQ listing. The holder of each share of the offering received a half warrant for $3.75 until November 5, 2024.
With higher costs due to the expansion of recruitment for their LANCER study in Brazil, Mexico and Canada, this new influx of cash can allow the company to run full steam ahead without compromising R&D.
As discussed in our initial coverage report (June 2021), http://www.more-ir.de/d/22609.pdf, we believe that the LANCER study could produce its first results in the fourth quarter of 2021 or the first quarter of 2022. The inclusion of new markets for patients recruitment indicates that the company is on track to meet their timeline. We believe that with the additional funds raised, the company could also increase the number of participants.
Cardiol Therapeutics also received approval from Health Canada for its CardiolRxTM for Acute Myocarditis Phase II Clinical Trial. The approval comes after the U.S. Food and Drug Administration (FDA) granted clearance to proceed with Cardiol Therapeutics' Investigational New Drug (IND) application to begin this trial, as announced by the company on August 24th, 2021. The trial's primary endpoints will be left ventricular function (ejection fraction and longitudinal strain) and myocardial edema (extracellular volume), both of which have been shown to predict long-term prognosis in patients with acute myocarditis after 12 weeks of double-blind therapy.
The presentation will be made via Zoom.
When: Nov. 24, 2021 at 3 p.m. Amsterdam, Berlin, Rome, Stockholm, Vienna.
Register here to attend:
After registration you will receive a confirmation email with information about dial-in details to participate in the webinar.
With best regards
18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.